{
    "nctId": "NCT01772472",
    "briefTitle": "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)",
    "officialTitle": "A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1487,
    "primaryOutcomeMeasure": "Invasive Disease-free Survival (IDFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patient, \\>/= 18 years of age\n* HER2-positive breast cancer\n* Histologically confirmed invasive breast carcinoma\n* Clinical stage T1-4/N0-3/M0 at presentation (patients with T1a/bN0 tumors will not be eligible)\n* Completion of preoperative systemic chemotherapy and HER2-directed treatment consisting of at least 6 cycles of chemotherapy with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab and at least 9 weeks of taxane-based therapy\n* Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes as specified in protocol\n* Pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy\n* An interval of no more than 12 weeks between the date of surgery and the date of randomization\n* Known hormone-receptor status\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate hematologic, renal and liver function\n* Screening Left ventricular ejection fraction (LVEF) \\>/= 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) after receiving neoadjuvant chemotherapy and no decrease in LVEF by more than 15% absolute points from the pre-chemotherapy LVEF. Or, if pre-chemotherapy LVEF was not assessed, the screening LVEF must be \\>/= 55% after completion of neoadjuvant chemotherapy.\n* For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of \\< 1% per year during the treatment period and for at least 7 months after the last dose of study drug\n* Documentation of hepatitis B virus and hepatitis C virus serology is required\n\nExclusion Criteria:\n\n* Stage IV (metastatic) breast cancer\n* History of any prior (ipsi- or contralateral breast cancer except lobular carcinoma in situ\n* Evidence of clinically evident gross residual or recurrent disease following preoperative therapy and surgery\n* Progressive disease during preoperative systemic therapy\n* Treatment with any anti-cancer investigational drug within 28 days prior to commencing study treatment\n* History of other malignancy within the last 5 years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other non-breast malignancies with a similar outcome to those mentioned above\n* Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons\n* Current NCI CTCAE (Version 4.0) Grade \\>/= 2 peripheral neuropathy\n* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin \\> 240 mg/m2; Epirubicin or Liposomal Doxorubicin-Hydrochloride (Myocet\u00ae) \\> 480 mg/m2; For other anthracyclines, exposure equivalent to doxorubicin \\> 240 mg/m2\n* Cardiopulmonary dysfunction as defined by protocol\n* Prior treatment with trastuzumab emtansine\n* Current severe, uncontrolled systemic disease\n* Pregnant or lactating women\n* Any known active liver disease, e.g. due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis\n* Concurrent serious uncontrolled infections requiring treatment or known infection with HIV\n* History of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}